Cancer Nanotechnology Training Program

 描述(申请人提供)：随着许多不同的基于纳米技术的癌症检测、诊断和治疗平台的快速发展，对医学博士和博士级别的科学家的巨大需求，他们不仅能够产生更多的癌症纳米材料，而且能够优化其生物学特性，并评估其安全性和临床疗效。西北大学(NU)拟议的新T32癌症纳米技术培训计划的目标是毕业受训人员，他们精通纳米技术的原理和工具，拥有良好的癌症生物学和临床肿瘤学工作知识，并能够将他们的纳米技术技能和知识应用于影响癌症患者的翻译研究。为了实现这些目标，培训计划将提供横跨癌症纳米技术主题的研究培训，提供广泛的教育课程，提供补充的知识基础，以及多方面的职业发展计划，为学员的学术生涯和其他与研究相关的职业生涯做准备。将建立多种机制来评估受训者、导师和整个计划的表现。学员将有机会获得罗伯特·H·鲁里综合癌症中心支持的一系列资源和项目，该中心将管理培训项目，所有18名培训项目导师都隶属于该中心。培训将在拥有纳米技术资源的环境中进行，包括NU的国际纳米技术研究所、医学生物纳米技术研究所和NU癌症纳米技术卓越中心。该计划的18名教官中的大多数都与这些纳米技术研究所中的一个或多个有联系。该计划将招收医学博士和博士实习生，我们要求在五年内每年为四名实习生提供支持。

 DESCRIPTION (provided by applicant): With the rapid development of many different nanotechnology-based platforms for cancer detection, diagnosis and therapy, there is a tremendous need for MD and PhD-level scientists who are capable not only of generating additional cancer nanomaterials but also of optimizing their biological properties, and evaluating their safety and clinical efficacy. The goal of the proposed new T32 Cancer Nanotechnology Training Program at Northwestern University (NU) is to graduate trainees who are well-versed in the principles and tools of nanotechnology, who have a good working knowledge of cancer biology and clinical oncology, and who can apply their nanotechnology skills and knowledge to translational research that impacts cancer patients. To accomplish these goals, the training program will provide research training that spans a continuum of cancer nanotechnology topics, an extensive educational curriculum that confers a complementary knowledge base, and a multifaceted career development program that prepares trainees for academic careers as well as for other research-related careers. Multiple mechanisms will be in place to evaluate the performance of the trainees, mentors, and the overall program. Trainees will have access to a wide array of resources and programs supported by the Robert H. Lurie Comprehensive Cancer Center, which will administer the training program and with which all 18 of the training program preceptors are affiliated. Training will occur within a milieu replete with nanotechnology resources, including those of NU's International Institute for Nanotechnology, the Institute for BioNanotechnology in Medicine, and the NU Center for Cancer Nanotechnology Excellence. Most of the program's 18 preceptors have ties to one or more of these nanotechnology institutes. The program will enroll a mix of MD and Ph.D. trainees, and we are requesting support for four trainees per year for five years.